

REFERENCIAS BIBLIOGRÁFICAS

1. Benutucci J, SIDA y Enfermedades asociadas. Diagnóstico, clínica y tratamiento; Segunda edición. Fundación de Ayuda al Inmunodeficiente; Argentina, pg 302-313; 2001.
2. Schaechter M, Medoff G, Microbiología. Mecanismos de las enfermedades infecciosas; Segunda edición. Editorial Médica Panamericana; Argentina, pg 607-611; 1994.
3. Goodman y Gilman, Las Bases Farmacológicas de la Terapéutica; Novena edición. McGraw-Hill Interamericana; México, pg. 1248-1251; 1998.
4. Velázquez G, Gómez R, SIDA enfoque integral; Segunda edición. Corporación para investigaciones biológicas; Colombia, pg 87-114; 1997.
5. Dolin R, Masur R, AIDS therapy; Churchill Livingstone. Philadelphia, pg 400-443; 1999.
6. Terrell Ch, Hermans P, Antifungal agents used for deep-seated mycotic infections. Mayo Clinic Proceedings 1987; 62: 1116-1128.
7. Graybill J, Craven P, Antifungal agents used in systemic mycoses activity and therapeutic use. Drug 1983; 25: 41-62.
8. Sarosi G, Amphotericin B still the gold standar for Antifungal therapy. Postgraduate Medicine 1990; 80 (1): 151-165.
9. World Health Organization, Amphotericin B. Who Drug Information 1991; 5 (3): 133-134.

10. Pathak A, Amphotericin B use in a community hospital, with special emphasis on side effects. Clin Infect Dis 1998; 26: 334-338.
11. Powderly W, Kobayashi G, Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med 1988; 84: 826-832.
12. Patel R, Antifungal agents. Part 1. Amphotericin B preparations and flucytosine. Mayo Clinic Proceedings 1998; 73 (12): 1205-1225;
13. Urs E, Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours randomized controlled trial. British Medical Journal 2001; 332: 579-565.
14. Ellis M, Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B. Antimicrob Agents Chemother 1992; 36 (1): 172-179.
15. Cruz J, Rapid intravenous infusion of amphotericin B: a pilot study. Am J Med 1992; 93: 123-130.
16. Oldfield E, Randomized double-blind trial of 1 versus 4 hours amphotericin B infusion duration. Antimicrob Agents Chemother 1990; 34 (7): 1402-1406.
17. Chia J, In vitro tumor necrosis factor induction assay for analysis of febrile toxicity associated with amphotericin B preparations. Antimicrob Agents Chemother 1990; 34 (5): 906-908.
18. Cleary JD, Effect of infusion rate on amphotericin B – associated febrile reactions. Drug Intelligence and Clinical Pharmacy 1988; 22 (10): 769-772.
19. Gigliotti F, Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B. J Infect Dis 1985; 165 (5): 784-789.

20. Goodwin S.D., Pretreatment regimens for adverse events related to infusión of amphotericin B. Clin Infect Dis 1995; 20: 755-61.
21. Gotz V, Effect of filtering Amphotericin B infusions on the incidence and severity of phlebitis and selected adverse reactions. Drug Intelligence and Clinical Pharmacy 1985; 19: 436-439.
22. Chan C, Tuazon C, Amphotericin B – induced thrombocytopenia. Ann Intern Med 1988; 96 (3): 332-333.
23. Lin A, Amphotericin B blunts erythropoietin response to anemia. J Infect Dis 1990; 161: 348-351.
24. Salama A, Acute immune hemolysis induced by a degradation product of amphotericin B. Blut 1989; 58 (2): 59-61.
25. Miller MA, Reversible hepatotoxicity related to amphotericin B; Can Med Ass J 1984; 131 (10): 1245-1247.
26. Gill J, Hepatotoxicity possibly caused by amphotericin B. Ann Pharmacother 1999; 33 (6): 683-685.
27. Barton C, Renal magnesium wasting associated with amphotericin B therapy. Am J Med 1984; 77: 471-474.
28. Patterson R, Renal tubular acidosis due to amphotericin B nephrotoxicity. Arch Intern Med 1971; 127: 241-244.
29. Burgess J, Nephrotoxicity of Amphotericin B, with emphasis on changes in tubular function; Am J Med 1972; 53: 77-89.
30. Heidemann H, Gerkens J, Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983; 75: 476-480.
31. Sawaya B, Amphotericin B nephrotoxicity the adverse consequences of altered membrane properties. J Am Soc of Nephrol 1995; 6 (2): 154-164.

32. Bates D, Su L, Correlates of acute renal failure in patients receiving parenteral amphotericin B. *Kidney International* 2001; 60: 1452-1459.
33. Bates D, Su L, Mortalidad y costos de la insuficiencia renal aguda asociada al tratamiento con anfotericina B. *Clin Infect Dis* 2001; 32: 686-693.
34. Varlam D, Apoptosis contributes to amphotericin B-induced nephrotoxicity; *Antimicrob Agents Chemother* 2001; 45 (3): 679-685.
35. Sabra R, Branch R, Amphotericin B nephrotoxicity. *Drug Saf* 1990; 5 (2): 94-108.
36. Luber A, Maa L, Risk factors for amphotericin B-induced nephrotoxicity. *J Antimicrob Chemother* 1999; 43: 267-271.
37. Harbath S, The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. *Am J Med* 2001; 111 (7): 528-534.
38. Fanos V, Cataldi L, Amphotericin B-induced nephrotoxicity, a review. *J Chemother* 2000; 12 (6): 463-470.
39. Wasan K, Conklin J, Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low – density lipoprotein cholesterol. *Clin Infect Dis* 1997; 24: 78-80.
40. Fisher M, Risk factors for amphotericin B-associated nephrotoxicity. *Am J Med* 1989; 87: 547-552.
41. Teruya J, Evaluación de la toxicidad por anfotericina B en pacientes infectados por el virus de inmunodeficiencia humana con meningitis criptocócica. Tesis de Bachiller; UPCH; 2001.
42. Dismukes W, Management of cryptococcosis. *Clin Infect Dis* 1993; 17 (suppl 2): S507-S512.

43. Larsen R, Treatment of cryptococcal; N Engl J Med 1997; 337 (21): 1557-1558.
44. Nelson M, Fisher M, The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection. AIDS 1994; 8: 651-654.
45. Dismukes W, Cryptococcal meningitis in patients with AIDS; J Infect Dis 1998; 157 (4): 624-628.
46. Powderly W, Therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1992; 14 (suppl 1): S54-S59.
47. Eng R, Bishburg E, Cryptococcal infections in patients with acquired immune deficiency syndrome; Am J Med 1986; 81: 19-23.
48. Vander Horst Ch, Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997; 337 (1): 15-21.
49. De Lalla F, Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: Reliability of relatively high doses administered over a relatively short period. Clin Infect Dis 1995; 20: 263-266.
50. Hsieh SM, Hung C, Efficacy and adverse effects of higher dose amphotericin B monotherapy for cryptococcal meningitis in patients with advance HIV infection. J Microbiol Immunol Infect 1998; 31 (4): 233-239.
51. Powderly W, Saag M, A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326 (12): 793-798.
52. Leenders A, Reiss P, Liposomal amphotericin B (ambisone) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS- associated cryptococcal meningitis. AIDS 1997; 11: 1463-1471.

53. Saag M, Powderly W, Comparison of amphotericin B with fluconazole in the treatment of acute AIDS – associated cryptococcal meningitis; The New Journal of Medicine 1992; 326 (1): 83-89.
54. Tolins J, Amphotericin versus Fluconazole in cryptococcal meningitis. N Engl J Med 1992; 326 (1): 1567-1568.
55. Fan-Havard P, Development of resistance in *Candida* isolates from patients receiving prolonged Antifungal therapy. Antimicrob Agents Chemother 1991; 35 (11): 2302-2305.
56. Villanueva A, Gotuzzo E, A randomized double-blind study of caspofungin versus amphotericin for the treatment of *Candida* esophagitis. Clin Infect Dis 2001; 33: 1529-1535.
57. He X, Tiballi R, Azole resistance in oropharyngeal *Candida albicans* strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994; 38 (10): 2495-2497.
58. Wheat J, Sarosi G, Practice guidelines for the management of patients with histoplasmosis. Clin Infect Dis 2000; 30: 688-695.
59. Wheat J, Conolly P, Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical finding, diagnosis and treatment, and review of the literature. Medicine 1990; 68 (6): 361-695.
60. Johnson P, Khardori N, Progressive disseminated histoplasmosis in patients with acquired immunodeficiency syndrome; Am J Med 1988; 85: 152-158.
61. McKinsey D, Prospective study of histoplasmosis in patients infected with human immunodeficiency virus: incidence, risk factors, and pathophysiology; Clin Infect Dis 1997; 24: 1195-1203.

62. Huang Ch, Disseminated histoplasmosis in the acquired immunodeficiency syndrome. Arch Intern Med 1987; 147: 1181-1184.
63. McKinsey D, Histoplasmosis in patients with AIDS: Efficacy of maintenance amphotericin B therapy. Am J Med 1992; 92: 225-227.
64. Bonner J, Alexander J, Disseminated histoplasmosis in patients with the acquired immune deficiency syndrome Am J Med 1984; 144: 2178-2180.
65. Kurtin P, Histoplasmosis in patients with acquired immunodeficiency syndrome Am J Clin Pathology 1990; 93: 367-372.
66. Wheat L, Histoplasmosis in the acquired immune deficiency syndrome; Am J Med 1987; 78: 205-210.
67. Carey C, Lee H, Manual Washington de Terapéutica médica; Décima edición. Masson, S.A; España; pg. 55-61; 1999.
68. Bonal J, Domínguez A, Farmacia Hospitalaria; Segunda edición. Editorial Médica Internacional S.A. España 1993; pg. 601-611.
69. Romero Y, Sáenz V, Incidencia de reacciones adversas a antibacterianos durante la profilaxis y tratamiento en pacientes del servicio de cirugía general HNGAI. Tesis de Bachiller; UNMSM; 2001.
70. Carrión C, Morales M, Susceptibilidad aumentada a reacciones adversas a medicamentos (RAMs) en pacientes VIH (+). A propósitos de 3 casos; Farmacia Hospitalaria 1998; 22: 39-40.
71. Salvia Ll. Mari A, Actuación farmacoterapéutica en el marco de un programa de Atención Farmacéutica; órgano internacional de expresión de la organización de farmacéuticos Iberoamericano 1999; 9(2) 40-43.